Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2013


Translational CNS Summit

21 May 2013 - 23 May 2013 - Boston, MA, USA



Bookmark and Share


Increase the translational potential of your CNS therapies

Bridge the Translational Gap

CNS diseases are a huge unmet medical need in our society. Why? Because CNS drug discovery is notoriously difficult. But for the companies that get it right and produce new successful therapeutics, the rewards, both commercially and socially will be huge. So what can be done to ensure more CNS drugs make it to market?

The problems drug developers face tend to be very similar across the industry. Unreliable animal models. Validating new biomarkers. Detecting if a drug has reached the brain. However the solutions to tackle these problems are different across the board. There is a real hunger for a consolidation of ideas to decide what is best practice.


Translational CNS is first and foremost a summit, a meeting of leading minds in the CNS field. Where the key issues can be discussed, where progress can be made, where people can decide how to mitigate risk of failure.

The agenda has been designed by experts from Eli Lilly, Takeda, Eisai and more. It will cover how to avoid the pitfalls that cause CNS drugs to fail and enable you to increase the clinical success rate of your CNS drugs

Key topics covered include:

Designing animal models with improved predictive validity

Optimizing the use of imaging within your clinical development

Identifying and validating new biomarkers of CNS disease

Bridging the gap between preclinical and clinical developmente the translational potential of your CNS therapies

Bridge the Translational Gap

CNS diseases are a huge unmet medical need in our society. Why? Because CNS drug discovery is notoriously difficult. But for the companies that get it right and produce new successful therapeutics, the rewards, both commercially and socially will be huge. So what can be done to ensure more CNS drugs make it to market?

The problems drug developers face tend to be very similar across the industry. Unreliable animal models. Validating new biomarkers. Detecting if a drug has reached the brain. However the solutions to tackle these problems are different across the board. There is a real hunger for a consolidation of ideas to decide what is best practice.

Translational CNS is first and foremost a summit, a meeting of leading minds in the CNS field. Where the key issues can be discussed, where progress can be made, where people can decide how to mitigate risk of failure.

The agenda has been designed by experts from Eli Lilly, Takeda, Eisai and more. It will cover how to avoid the pitfalls that cause CNS drugs to fail and enable you to increase the clinical success rate of your CNS drugs

Key topics covered include:

Designing animal models with improved predictive validity

Optimizing the use of imaging within your clinical development

Identifying and validating new biomarkers of CNS disease

Bridging the gap between preclinical and clinical development



Further information
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!